Given the lack of a consensus on the effects of PPIs in patients with severe acute respiratory syndrome coronavirus-2, these medications should be deprescribed or therapy decreased to the lowest effective dose, when possible.
Recently, siponimod and ozanimod were FDA-approved for treating MS, an autoimmune disease that affects the central nervous system of nearly 1 million people in the United States.
Based on lipid levels and estimates of atherosclerotic cardiovascular disease risk, statins are used in combination with other lipid-lowering therapies.